Genome editing or genome engineering is the modification of the genome in the living organism. This is different from the traditionally used genetic engineering techniques that required insertion of the genetic element in the host genome. The novel genome editing method targets the specific genome that requires alteration or modification to specific locations. The technique effectively and accurately changes the DNA of an organism. One of the recent improved approaches to genome editing is popularly known as CRISPR-Cas9. This system has created numerous opportunities in the science community owing to its accuracy, speed, and relatively better efficiency than other available techniques. Genome engineering focuses on curing the genetic disorders in human. A group of prominent scientists are stressing on a more cautious approach for the application of genome engineering in human germ lines. This is because any non-targeted DNA harm may result in higher cellular toxicities.
The ongoing pandemic of COVID-19 has impacted the researches and studies associated with genome editing or genome engineering. Researchers have developed novel CRISPR screen technology that targets RNA. The team influenced the technology for crucial analysis. The prevalent corona virus comprises an RNA genome and not DNA genome. In addition, CRISPR technology have assisted scientists to identify genes that play a major role in cancer immunotherapy, sickle-cell anemia, lung cancer, and more.
Major Key Players of the Genome Editing/Genome Engineering Market are:Thermo Fisher Scientific, Lonza, Merck, Horizon Discovery Group, Integrated DNA Technologies, New England Biolabs (US), GenScript (US), Sangamo BioSciences (US), OriGene Technologies (US), Transposagen Biopharmaceuticals (US), Editas Medicine (US), and CRISPR Therapeutics (Switzerland)., among others.
Read More @ http://www.sbwire.com/press-releases/impact-of-covid-19-on-genome-editinggenome-engineering-market-to-witness-huge-growth-by-2030-thermo-fisher-scientific-lonza-merck-1290502.htm
The ongoing pandemic of COVID-19 has impacted the researches and studies associated with genome editing or genome engineering. Researchers have developed novel CRISPR screen technology that targets RNA. The team influenced the technology for crucial analysis. The prevalent corona virus comprises an RNA genome and not DNA genome. In addition, CRISPR technology have assisted scientists to identify genes that play a major role in cancer immunotherapy, sickle-cell anemia, lung cancer, and more.
Major Key Players of the Genome Editing/Genome Engineering Market are:Thermo Fisher Scientific, Lonza, Merck, Horizon Discovery Group, Integrated DNA Technologies, New England Biolabs (US), GenScript (US), Sangamo BioSciences (US), OriGene Technologies (US), Transposagen Biopharmaceuticals (US), Editas Medicine (US), and CRISPR Therapeutics (Switzerland)., among others.
Read More @ http://www.sbwire.com/press-releases/impact-of-covid-19-on-genome-editinggenome-engineering-market-to-witness-huge-growth-by-2030-thermo-fisher-scientific-lonza-merck-1290502.htm
No comments:
Post a Comment